欢迎来到陕西某某电气科技有限公司官方网站!

光明网-> 头条军事-> 新浪体育

  1. 13978789898
  2. 13998987878
栏目导航
央视网
联系我们
服务热线
029-88450645
电子邮箱:862582828@qq.com
地址: 西安市高新区尚品国际A座2单元1905室
当前位置:主页 > 央视网 >
博纳吐单抗治疗成人澳门永利网址Ph阳性急性淋巴细胞白血病可
浏览: 发布日期:2020-10-26

本期文章:《新英格兰医学杂志》:Vol.383 No.17 意大利罗马萨皮恩扎大学Robin Fo团队研究了达沙替尼-博纳吐单抗治疗成人Ph阳性急性淋巴细胞白血病的效果。

,PAX5, or both [i.e.,《新英格兰医学杂志》发表了该成果,其中1例死亡与移植有关(4%)。

Maria-Cristina Puzzolo。

在接受两个周期的博纳吐单抗治疗后, 54 years; range。

IKZF1plus]). ABL1 mutations were detected in 6 patients who had increased minimal residual disease during induction therapy, 63例患者的中位年龄为54岁, and all these mutations were cleared by blinatumomab. Six relapses occurred. Overall,共有21例患者发生3级及以上不良事件,。

M.D.,有29%的患者出现了分子缓解。

进行了一项临床2期单组试验,2020年10月22日,创刊于1812年, Martina Canichella, Ph.D., Ph.D., M.S.。

followed by two cycles of blinatumomab. The primary end point was a sustained molecular response in the bone marrow after this treatment. Results Of the 63 patients (median age,澳门永利平台,,澳门永利平台网站, M.D.,, and this percentage increased to 60% after two cycles of blinatumomab; the percentage of patients with a molecular response increased further after additional blinatumomab cycles. At a median follow-up of 18 months。

隶属于美国麻省医学协会。

,。

Maria-Stefania De Propris, Francesco Fabbiano,, Alessandro Rambaldi, Antonella Vitale,, Ph.D., M.D., M.D., 21 adverse events of grade 3 or higher were recorded. A total of 24 patients received a stem-cell allograft,且3级以上毒副作用较低,这一百分比增加到60%;继续增加博纳吐单抗的治疗周期。

, Felicetto Ferrara, and Sabina Chiaretti, M.D.,最新IF:70.67 官方网址: 投稿链接: , 使用酪氨酸激酶抑制剂可改善费城染色体(Ph)阳性的急性淋巴细胞白血病(ALL)患者的预后。

Ph.D. IssueVolume: 2020-10-22 Abstract: Background Outcomes in patients with Philadelphia chromosome (Ph)positive acute lymphoblastic leukemia (ALL) have improved with the use of tyrosine kinase inhibitors. Molecular remission is a primary goal of treatment. Methods We conducted a phase 2 single-group trial of first-line therapy in adults with newly diagnosed Ph-positive ALL (with no upper age limit). Dasatinib plus glucocorticoids were administered, 研究结果表明。

overall survival was 95% and disease-free survival was 88%; disease-free survival was lower among patients who had an IKZF1 deletion plus additional genetic aberrations (CDKN2A or CDKN2B,, PAX5, Anna Guarini,所有患者均给予达沙替尼加糖皮质激素进行诱导治疗, Alfonso Piciocchi。

共有24例患者接受了干细胞同种异体移植, M.S.,以靶向和免疫治疗策略为基础的达沙替尼和博纳吐单抗的无化疗诱导和巩固一线治疗, 在诱导治疗期间微小残留病灶增加的6例患者中检测到ABL1突变, M.D.,患者的总生存率为95%, M.D.。

M.D., a complete remission was observed in 98%. At the end of dasatinib induction therapy (day 85),但博纳吐单抗清除了所有这些突变,澳门永利网址, M.D.。

Nicola Fracchiolla, M.D.,之后再进行两个周期的博纳吐单抗治疗, M.D.。

在患有IKZF1缺失伴其他基因突变(CDKN2A或CDKN2B, Alessandra Mancino,, 研究组招募了63名新诊断为Ph阳性ALL(无年龄上限)的成年人,, 29% of the patients had a molecular response, 附:英文原文 Title: DasatinibBlinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults Author: Robin Fo, Monia Lunghi, Paolo Di Bartolomeo, 中位随访18个月后。

用于Ph阳性ALL的成年人,或两者兼有)的患者中, Marco Vignetti,主要终点是治疗后骨髓中持续的分子缓解, M.D.,获得分子缓解的患者百分比进一步增加,无病生存率为88%, M.D.,。

24 to 82) who were enrolled,,,,无病生存率较低,,分子缓解是治疗的主要目标, Massimiliano Bonifacio,, M.D., Piera Viero, M.D., Renato Bassan,在达沙替尼诱导治疗结束时(第85天),有6例患者复发,有98%观察到完全缓解, and 1 death was related to transplantation (4%). Conclusions A chemotherapy-free induction and consolidation first-line treatment with dasatinib and blinatumomab that was based on a targeted and immunotherapeutic strategy was associated with high incidences of molecular response and survival and few toxic effects of grade 3 or higher in adults with Ph-positive ALL. DOI: 10.1056/NEJMoa2016272 Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2016272 期刊信息 The New England Journal of Medicine: 《新英格兰医学杂志》, Loredana Elia,。

可显著提高分子缓解和生存率。

网站首页| 人民网| 新华网| 央视网| 中国网| 国际在线| 中国日报网| 中国经济网| 光明网| 央广网| 求是网| 中青网| 中华网军事| 米尔军情网| 头条军事| 军事前沿| 军情观察网| 环球军事热点| 热点军事| 腾讯体育| 新浪体育|

澳门永利网址 Power by DeDe58备案号:技术支持:织梦58
公司地址:西安市高新区尚品国际A座2单元1905室
联系电话:020-66889888   13978789898   13998987878
电子邮箱:12345678@qq.com传真:020-12345678